Eronib
Generic Name
Erlotinib 150 mg Tablet
Manufacturer
Everest Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| eronib 150 mg tablet | ৳ 700.00 | ৳ 9,800.00 |
Description
Overview of the medicine
Eronib 150 mg Tablet contains Erlotinib, an anti-cancer medication used to treat certain types of non-small cell lung cancer (NSCLC) and pancreatic cancer. It works by blocking the action of a specific protein (EGFR) that helps cancer cells grow and multiply.
Uses & Indications
Dosage
Adults
For NSCLC: 150 mg orally once daily. For Pancreatic cancer: 100 mg orally once daily in combination with gemcitabine.
Elderly
No specific dose adjustment is required based on age alone.
Renal_impairment
No specific dose adjustment is required in patients with mild to moderate renal impairment. Use with caution in severe renal impairment.
How to Take
Take orally, at least one hour before or two hours after a meal. Swallow the tablet whole with water.
Mechanism of Action
Erlotinib reversibly inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). This inhibition blocks the signal transduction pathways implicated in cell proliferation and survival of cancer cells.
Pharmacokinetics
Onset
Clinical effects may take several weeks to manifest.
Excretion
Mainly excreted in the feces (83%) as metabolites, with a small amount (8%) excreted renally.
Half life
The elimination half-life is approximately 36.2 hours.
Absorption
Approximately 60% absorbed after oral administration; peak plasma concentrations reached about 4 hours post-dose. Bioavailability is increased with food.
Metabolism
Primarily metabolized in the liver by cytochrome P450 enzymes (CYP3A4 and to a lesser extent CYP1A2).
Side Effects
Contraindications
- •Severe hypersensitivity to Erlotinib or any of its excipients.
Drug Interactions
Warfarin
May increase INR and bleeding risk; monitor INR closely.
CYP3A4 Inhibitors (e.g., ketoconazole)
May increase Erlotinib exposure, requiring dose reduction.
CYP3A4 Inducers (e.g., rifampicin, phenytoin)
May decrease Erlotinib exposure, requiring dose increase or alternative treatment.
Proton Pump Inhibitors (PPIs) and H2-receptor antagonists
May significantly reduce Erlotinib absorption; avoid co-administration or separate dosing.
Storage
Store below 30°C in a dry place. Protect from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose are mainly severe rash and diarrhea. Treatment of overdose should consist of general supportive measures. There is no specific antidote for Erlotinib overdose.
Pregnancy & Lactation
Pregnancy Category D. Erlotinib may cause fetal harm when administered to a pregnant woman. It is not known whether Erlotinib is excreted in human milk; due to the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from the date of manufacture, consult the product packaging for specific details.
Availability
Pharmacies, Hospitals
Approval Status
FDA Approved
Patent Status
Patent expired in many regions; generics available
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in